Tranexamic acid (trade name: Cyklokapron) prevents the breakdown of fibrin that has already formed and is administered in addition to other measures for acute bleeding and unexplained coagulation disorders. A large randomized trial (CRASH-2)1 showed that administration of tranexamic acid improves mortality in actively bleeding trauma patients. The use of tranexamic acid remains controversial.
References